The present invention relates to a novel crystalline form of 4-(5-(
1
R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form.
本发明涉及一种新的晶体形式,即4-(5-(1R)-1-[5-(3-
氯苯基)
异恶唑-3-基]乙氧基}-4-甲基-4H-
1,2,4-三唑-3-基)
吡啶。此外,本发明还涉及使用该新晶体形式治疗胃肠道疾病,含有它的药物组合物以及制备该新晶体形式的方法。